| [1] |
Sahasrabuddhe VV. Cervical cancer: precursors and prevention[J]. Hematol Oncol Clin North Am, 2024, 38(4): 771-781. DOI: 10.1016/j.hoc.2024.03.005.
|
| [2] |
Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative[J]. Lancet Glob Health, 2023, 11(2): e197-e206. DOI: 10.1016/S2214-109X(22)00501-0.
|
| [3] |
Wu Q, Lu S, Zhang L, et al. LncRNA HOXA-AS2 activates the notch pathway to promote cervical cancer cell proliferation and migration[J]. Reprod Sci, 2021, 28(10): 3000-3009. DOI: 10.1007/s43032-021-00626-y.
|
| [4] |
Huang W, Liu J, Xu K, et al. PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: from bench to bed[J]. Front Oncol, 2022, 12: 849352. DOI: 10.3389/fonc.2022.849352.
|
| [5] |
Chen Z, Dong D, Zhu Y, et al. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma[J]. FASEB J, 2021, 35(3): e21401. DOI: 10.1096/fj.202000528RR.
|
| [6] |
Balança CC, Salvioni A, Scarlata CM, et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells[J]. JCI Insight, 2021, 6(2): 142513. DOI: 10.1172/jci.insight.142513.
|
| [7] |
Zhang H, Tan S, Fang C, et al. PD-1/PD-L1 correlates with the efficacy of the treatment of concurrent chemoradiotherapy in cervical cancer[J]. Front Oncol, 2022, 12: 858164. DOI: 10.3389/fonc.2022.858164.
|
| [8] |
中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 474-489. DOI: 10.19401/j.cnki.1007-3639.2021.06.06.
|
| [9] |
Zhang Y, Wang C, Zhao Z, et al. Survival outcomes of 2018 FIGO stage ⅢC versus stages ⅢA and ⅢB in cervical cancer: a systematic review with meta-analysis[J]. Int J Gynaecol Obstet, 2023, 165(3): 959-968. DOI: 10.1002/ijgo.15218.
|
| [10] |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.
|
| [11] |
Włoszek E, Krupa K, Skrok E, et al. HPV and cervical cancer-biology, prevention, and treatment updates[J]. Curr Oncol, 2025, 32(3): 122. DOI: 10.3390/curroncol32030122.
|
| [12] |
Nguyen T, Nougaret S, Castillo P, et al. Cervical cancer in the pregnant population[J]. Abdom Radiol (NY), 2023, 48(5): 1679-1693. DOI: 10.1007/s00261-023-03836-x.
|
| [13] |
Peng X, Zhu Y, Han Y, et al. Enhancing anti-tumor immunity by targeting BATF and the STAT1/PD-L1 pathway in cervical carcinoma[J]. Cell Mol Life Sci, 2025, 82(1): 353. DOI: 10.1007/s00018-025-05792-9.
|
| [14] |
Petrică LA, Deacu M, Cozaru GC, et al. Interplay between immune microenvironment CD8+ tumor-infiltrating lymphocytes and PD-L1 expression as prognostic markers in invasive cervical squamous cell carcinoma[J]. Medicina (Kaunas), 2025, 61(11): 2007. DOI: 10.3390/medicina61112007.
|
| [15] |
Solorzano-Ibarra F, Alejandre-Gonzalez AG, Ortiz-Lazareno PC, et al. Cataloging circulating CD3+CD56+ NKT-like cells through a series of stimulating (NKG2D and DNAM-1) and inhibitory (PD-1, TIGIT, and Tim-3) immune checkpoint receptors in women diagnosed with precancerous cervical lesions or invasive cervical carcinoma[J]. Immunol Lett, 2024, 269: 106889. DOI: 10.1016/j.imlet.2024.106889.
|
| [16] |
Conde-Rodríguez I, Pérez-Picazo S, Vázquez-Zamora VJ, et al. Serum soluble Tim-3 is elevated in patients with cervical cancer and is higher in advanced clinical stages[J]. Biomed Rep, 2025, 22(5): 90. DOI: 10.3892/br.2025.1968.
|
| [17] |
陈秀敏, 吴熊军, 许文彬, 等. T细胞免疫球蛋白黏蛋白分子3对宫颈癌细胞生物学行为及肿瘤免疫微环境的影响[J]. 中国免疫学杂志, 2023, 39(11): 2282-2287. DOI: 10.3969/j.issn.1000-484X.2023.11.008.
|
| [18] |
García-Barrientos NT, Solorzano-Ibarra F, Klimov-Kravtchenko K, et al. T cell exhaustion in the cervical cancer tumor microenvironment: PD-1 overexpression and co-expression with TIGIT, Tim-3, LAG-3, and NKG2A[J]. Cancers (Basel), 2025, 17(22): 3627. DOI: 10.3390/cancers17223627.
|
| [19] |
张燕萍, 谌伦华, 张娟, 等. PD-1/PD-L1抑制剂治疗妇科常见恶性肿瘤的疗效及安全性的meta分析[J]. 中国计划生育学杂志, 2025, 33(3): 509-519. DOI: 10.3969/j.issn.1004-8189.2025.03.002.
|
| [20] |
Martinez-Cannon BA, Colombo I. The evolving role of immune check- point inhibitors in cervical and endometrial cancer[J]. Cancer Drug Resist, 2024, 7: 23. DOI: 10.20517/cdr.2023.120.
|
| [21] |
Solorzano-Ibarra F, Alejandre-Gonzalez AG, Ortiz-Lazareno PC, et al. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis[J]. Clin Exp Immunol, 2021, 204(1): 78-95. DOI: 10.1111/cei.13561.
|
| [22] |
Gorvel L, Panouillot M, Rouvière MS, et al. Tertiary lymphoid structures are associated with enhanced macrophage activation and immune checkpoint expression and predict outcome in cervical cancer[J]. Cancer Immunol Res, 2025, 13(5): 712-728. DOI: 10.1158/2326-6066.CIR-24-0979.
|
| [23] |
Jumaniyazova E, Lokhonina A, Dzhalilova D, et al. The role of macrophages in various types of tumors and the possibility of their use as targets for antitumor therapy[J]. Cancers (Basel), 2025, 17(3): 342. DOI: 10.3390/cancers17030342.
|
| [24] |
Maksimova A, Tyrinova T, Chernykh E. TIM-3+ macrophages: insights into their role in cancer and inflammation[J]. Int J Mol Sci, 2026, 27(2): 840. DOI: 10.3390/ijms27020840.
|
| [25] |
Zhang J, Xu Y, Han X, et al. Galectin-9 promotes colon cancer development by polarizing macrophages toward the M2 phenotype[J]. Cancer Genet, 2025, 298-299: 141-150. DOI: 10.1016/j.cancergen.2025.09.006.
|
| [26] |
姜冉然, 赵利红, 嵇绍干. 巨噬细胞极化与程序性死亡蛋白-1表达对非小细胞肺癌放疗抵抗及预后的影响[J]. 中华肿瘤防治杂志, 2026, 33(6): 370-378. DOI: 10.16073/j.cnki.cjcpt.2026.06.04.
|
| [27] |
Jiang X, Zhou T, Xiao Y, et al. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis[J]. Oncoimmunology, 2016, 5(9): e1211219. DOI: 10.1080/2162402X.2016.1211219.
|
| [28] |
Wang Z, Wang B, Feng Y, et al. Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer[J]. J Immunother Cancer, 2024, 12(8): e009024. DOI: 10.1136/jitc-2024-009024.
|
| [29] |
Yan M, Zhang Y, Chang S. Chitosan nanoparticles loaded with TGF-β1 inhibit cervical cancer cell progression through down-regulation of microRNA-155 and activation of Tim-3 pathway[J]. J Biomed Nanotechnol, 2021, 17(9): 1850-1857. DOI: 10.1166/jbn.2021.3146.
|
| [30] |
Tang W, Wang L, Li X, et al. Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer[J]. Gynecol Oncol, 2026, 205: 17-26. DOI: 10.1016/j.ygyno.2025.12.007.
|